A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Acta oncologica

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/02841860600791483PMID 17450469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)

  2005cited by this paper
• Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

  2005cited by this paper
• Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients

  2005cited by this paper
• Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

  2004cited by this paper
• 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.

  2004cited by this paper
• Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.

  2004cited by this paper
• Short-Time Infusion of Oxaliplatin (Eloxatin®) in Combination with Capecitabine (Xeloda®) in Patients with Advanced Colorectal Cancer

  2003cited by this paper
• Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

  2003cited by this paper
• Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

  2002cited by this paper
• Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

  2002cited by this paper
• Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

  2002cited by this paper
• Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of

  2000cited by this paper
• Paclitaxel, 5‐fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

  1999cited by this paper
• Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.

  1999cited by this paper
• A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

  1994cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF).

  1987cited by this paper
• Treatment of Advanced Gastric Cancer with DDP (Cisplatin), Adriamycin, and 5-FIuorouracil (DAF)

  1987cited by this paper
• Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU.

  1986cited by this paper
• Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.

  1986cited by this paper
• Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.

  1986cited by this paper
• An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).

  1984cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer

  2022cites this paper
• Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases

  2021cites this paper
• Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases

  2020cites this paper
• Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer

  2020cites this paper
• Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.

  2020cites this paper
• [Successful treatment of unresectable advanced gastric cancer with bladder metastasis using mFOLFOX6:a case report].

  2019cites this paper
• FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

  2019cites this paper
• Oxaliplatin , 5-Fluorouracil and Leucovorin ( FOLFOX-4 ) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

  2016cites this paper
• Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX

  2016cites this paper
• Ramucirumab for the treatment of gastroesophageal cancers

  2015cites this paper
• Blood neutrophil–lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4

  2014cites this paper
• Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers

  2014cites this paper
• Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.

  2014cites this paper
• Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy

  2014cites this paper
• Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy

  2013cites this paper
• Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer

  2013cites this paper
• The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer

  2013cites this paper
• A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

  2013cites this paper
• Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy

  2013cites this paper
• Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells

  2012cites this paper
• A Phase II Trial of 5-Fluorouracil, Leucovorin and Mitomycin C in Patients with Advanced Gastric Cancer

  2011cites this paper
• Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.

  2011cites this paper
• Multidisciplinary management of gastric cancer

  2010cites this paper
• Update on Anti-EGFR Targeted Therapy

  2009cites this paper
• Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

  2009cites this paper
• Update on Anti-EGFR Therapy

  2009influential citation
• Oxaliplatin Combined with Continuous Infusion of 5-Fluorouracil as First-Line Chemotherapy in Patients with Metastatic or Recurrent Gastric Adenocarcinoma

  2009cites this paper
• Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis

  2009cites this paper
• Advanced gastric cancer: a disease of diverse clinical biology.

  2009cites this paper
• Follow up your unexpected clinical observations!

  2009cites this paper
• Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer

  2009influential citation
• Treatment of advanced gastric carcinoma patients with calcium folinate, a 5-fluorouracil bolus and continous infusion with 5-fluorouracil combined with oxaliplatin

  2008cites this paper
• Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer

  2008cites this paper
• Current approaches to gastric cancer in Korea.

  2008cites this paper
• Upper gastrointestinal tumors: current status and future perspectives

  2008cites this paper
• A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.

  2007influential citation
• A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.

  2007cites this paper